Investigating heart failure treatment with Baxdrostat and Dapagliflozin
Official title: A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death
Run by AstraZeneca · NCT06677060 · Data updated 2026-11-12
This study is testing if a new combination of two medications can help adults over 40 with heart failure, type 2 diabetes, and heart disease feel better and live longer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 11300 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 977 sites (Birmingham, Alabama and 976 other locations) |
| Status | Recruiting |
| Started | March 14, 2025 |
| Main results expected | December 17, 2029 |
| Study ends | December 17, 2029 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT06677060 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men and women aged 40 and older with type 2 diabetes, established cardiovascular disease, and a history of hypertension.
✕Probably not a fit
Patients without a diagnosis of type 2 diabetes or those who do not have established cardiovascular disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of Baxdrostat in combination with Dapagliflozin in treating heart failure among adults aged 40 and older with type 2 diabetes and established cardiovascular disease. Participants will undergo a pre-screening period to identify eligibility, followed by a screening phase where they will be assessed for inclusion criteria. Those who qualify will receive either the combination treatment or a placebo alongside Dapagliflozin. The study seeks to determine the impact of this treatment on heart failure and cardiovascular death.
Why it matters
Potential benefit: If successful, this treatment could significantly improve outcomes for patients with heart failure and reduce cardiovascular mortality.
How similar studies have gone: Other studies have shown promising results with similar combinations of treatments for heart failure, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants of any sex and gender must be ≥ 40 years old at the time of signing the informed consent. * Diagnosed with T2DM and requiring treatment * Established CV disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease) * History of HTN and an SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the Randomisation Visit. * At least one additional risk factor for HF: * Age ≥ 70 years * UACR \> 20 mg/g * eGFR \< 60 mL/min/1.73 m2 * History of polyvascular disease (at least two of: ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease) * History of atrial fibrillation or atrial flutter * NT-proBNP \> 125 ng/L Exclusion Criteria: * Previously confirmed diagnosis and treatment of heart failure * An eGFR \< 30 mL/min/1.73 m2 at screening * Known hyperkalaemia, defined as potassium ≥ 5.5 mmol/L within 3 months prior to screening * Type 1 diabetes mellitus or uncontrolled T2DM with HbA1c \> 10.5% (\> 91 mmol/mol) at screening * Serum sodium \< 135 mmol/L at screening, determined as per central laboratory assessment * Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, carotid angioplasty, or cardiac surgery, within 3 months prior to randomisation * Myocardial infarction within 3 months prior to randomisation, or within 1 month prior to randomisation when there is no further planned revascularisation * Percutaneous coronary intervention within 1 month prior to randomisation * Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history * Documented history of adrenal insufficiency * Any dialysis (including for acute kidney injury) within 3 months prior to screening * Any acute kidney injury within 3 months prior to screening * Prohibited concomitant medications
Where it's running
-
Research Site
Birmingham, Alabama, United States Recruiting -
Research Site
Centreville, Alabama, United States Recruiting -
Research Site
Fairhope, Alabama, United States Recruiting -
Research Site
Huntsville, Alabama, United States Recruiting -
Research Site
Mobile, Alabama, United States Recruiting -
Research Site
Sheffield, Alabama, United States Recruiting
Show 44 more locations
-
Research Site
Vestavia Hills, Alabama, United States Recruiting -
Research Site
Gilbert, Arizona, United States Recruiting -
Research Site
Tempe, Arizona, United States Recruiting -
Research Site
Tucson, Arizona, United States Recruiting -
Research Site
Huntington Beach, California, United States Recruiting -
Research Site
Inglewood, California, United States Recruiting -
Research Site
La Jolla, California, United States Recruiting -
Research Site
Lincoln, California, United States Recruiting -
Research Site
Loma Linda, California, United States Recruiting -
Research Site
Los Angeles, California, United States Recruiting -
Research Site
Los Angeles, California, United States Recruiting -
Research Site
Sacramento, California, United States Recruiting -
Research Site
San Diego, California, United States Recruiting -
Research Site
San Dimas, California, United States Recruiting -
Research Site
San Francisco, California, United States Recruiting -
Research Site
Santa Maria, California, United States Recruiting -
Research Site
Thousand Oaks, California, United States Recruiting -
Research Site
Aurora, Colorado, United States Recruiting -
Research Site
Englewood, Colorado, United States Recruiting -
Research Site
Bridgeport, Connecticut, United States Recruiting -
Research Site
Stamford, Connecticut, United States Recruiting -
Research Site
Waterbury, Connecticut, United States Recruiting -
Research Site
Crystal River, Florida, United States Recruiting -
Research Site
Fort Myers, Florida, United States Recruiting -
Research Site
Jacksonville, Florida, United States Recruiting -
Research Site
Lakeland, Florida, United States Recruiting -
Research Site
Miami, Florida, United States Recruiting -
Research Site
Miami, Florida, United States Recruiting -
Research Site
Miami, Florida, United States Recruiting -
Research Site
Miami Lakes, Florida, United States Recruiting -
Research Site
Orlando, Florida, United States Recruiting -
Research Site
Palmetto Bay, Florida, United States Recruiting -
Research Site
Saint Augustine, Florida, United States Recruiting -
Research Site
Atlanta, Georgia, United States Recruiting -
Research Site
Canton, Georgia, United States Recruiting -
Research Site
Columbus, Georgia, United States Recruiting -
Research Site
Cordele, Georgia, United States Recruiting -
Research Site
Suwanee, Georgia, United States Recruiting -
Research Site
Tucker, Georgia, United States Recruiting -
Research Site
Woodstock, Georgia, United States Recruiting -
Research Site
Idaho Falls, Idaho, United States Recruiting -
Research Site
Champaign, Illinois, United States Recruiting -
Research Site
Chicago, Illinois, United States Recruiting -
Research Site
Chicago, Illinois, United States Recruiting
+927 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.